This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
After stent implantation, a three-month regimen of dual antiplatelet therapy (DAPT) was more effective than a one-month regimen at reducing adverse events without increasing bleeding risk in patients with a high bleeding risk (HBR), according to a Late-Breaking Clinical Trial presented at ACC.25 25 in Chicago.
A recent study published in JACC: Cardiovascular Interventions has provided new insights into the long-term management of patients suffering from recurrent in-stent restenosis (ISR), a condition presenting notable challenges in cardiovascular treatment. Original article: Koch T et al. The median follow-up period was 10.3
Drug-eluting stents (DES) play a crucial role in treating coronary artery disease (CAD) by preventing restenosis. These stents are coated with drug carriers that release antiproliferative drugs within the vessel. Out of 5,778 articles, we meticulously screened them based on predefined inclusion and exclusion criteria.
The goal of the REC-CAGEFREE I trial was to assess the safety and efficacy of a paclitaxel-coated balloon (DCB) compared to drug-eluting stent (DES) implantation among patients with coronary in-stent restenosis.
One of the most common questions I get is, “ Do I need a stent to treat my heart disease?” ” Typically, several of this person’s friends have had stents, so it seems natural to ask. First, we must understand what a stent is and why it is used. The stent ‘unblocks’ it. Flow is restored.
Original article: Gaba P et al. Pooled data from four trials were analyzed, encompassing patients undergoing PCI or CABG for left main disease. These findings underscore the importance of individualized treatment approaches in left main disease management. Circulation. 2024;149:00–00.
The goal of the INFINITY-SWEDEHEART trial was to compare the efficacy of the DynamX bioadaptor, a novel coronary implantable device, to a contemporary drug-eluting stent (DES) in the treatment of coronary artery disease requiring percutaneous coronary intervention (PCI).
The goal of the DCB-BIF trial was to assess the efficacy of drug-coated balloon (DCB) angioplasty of residual side branch stenosis in coronary bifurcation lesions treated with a provisional stenting strategy.
Use of intravascular lithotripsy (IVL) for the treatment of in-stent restenosis (ISR), although off-label, may be safe and feasible, according to a study reviewing data from the ACC's CathPCI Registry published in JACC: Cardiovascular Interventions.
Independent predictors of aortic valve complex and perivalvular thrombus included a small maximum stent diameter at the valve level and a low body surface area. Original article: Choi Y et al. Specifically, 14.2% of patients exhibited leaflet thrombus, while 37.0% had perivalvular thrombus. J Am Coll Cardiol Intv 2023;16:2967–2981.
IntroductionVertebral artery stenting represents a viable option in treating symptomatic vertebral artery atherosclerotic stenosis. We included articles reporting patients > 18 years old with symptomatic extracranial vertebral artery stenoses due to atherosclerosis treated with stenting (with or without angioplasty).
Methods We conducted a comprehensive search for articles on PubMed and Embase using search strategies which yielded 4,061 articles. After full-text screening, 66 articles were included for systematic review, and 62 articles were further selected for meta-analysis. Overall, 55 (83.3%) studies were at low risk of bias.
Angiogram: Widely patent RCA and LAD stents. Therefore, no stent was placed. (No It is proven better than angiography alone in stable angina , and also has been shown to improve decisions on stenting non-culprit lesions in ACS. We are told that this middle-aged male patient has a history of prior MI with stents.
A strategy of drug-coated balloon (DCB) angioplasty with rescue stenting did not achieve noninferiority compared with intended drug-eluting stent (DES) deployment for patients with de novo, noncomplex coronary artery lesions, according to finding from the REC-CAGEFREE I trial presented at ESC Congress 2024 in London and simultaneously published in (..)
The goal of the STOPDAPT-2 trial was to evaluate 1-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT among patients undergoing percutaneous coronary intervention (PCI).
The goal of the AGENT IDE trial was to assess the safety and efficacy of a paclitaxel-coated balloon (drug-coated balloon; DCB) to conventional balloon angioplasty among patients with coronary in-stent restenosis (ISR).
Abstract: The mechanism of in-stent restenosis (ISR) remains elusive, and in-stent neoatherosclerosis (ISNA) may hold siginificant pathophysiological implications. The mechanism of in-stent restenosis (ISR) remains elusive, and in-stent neoatherosclerosis (ISNA) may hold siginificant pathophysiological implications.
The near-immediate or instant feedback learning process by which the heart responds to any new invasive procedural variation facilitates each new change; be it drug-eluting stent, drug-coated balloon, or both in different combinations and permutations.
Old ‘NSTEMI’ A history of coronary artery disease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stent thrombosis. The patient had a history of ‘NSTEMI’ a decade prior, with an RCA stent. Does this change your interpretation?
The goal of the HOST-EXAM trial was to assess the safety and efficacy of clopidogrel vs. aspirin monotherapy among patients who had completed the required duration of dual antiplatelet therapy (DAPT) therapy postdrug-eluting stent (DES) percutaneous coronary intervention (PCI).
In this article, we’ll explore some of the leading fellowship specialties, what they entail, and the career paths they open for doctors committed to continuous learning and professional growth. These fellowships are designed for those with a keen interest in mastering procedures that demand precision and expertise.
We present our experience performing concurrent lead extraction and dilation/stenting of venous pathways, including patients with complete venous obstruction. Three patients had complete obstructions, three required stenting of their innominate veins and three required recanalization of their femoral vessels. years (range 3.6−35.3
In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation.
The goal of the STOPDAPT-3 trial was to compare the safety and efficacy of an aspirin-free strategy among patients undergoing percutaneous coronary intervention (PCI) or at high bleeding risk.
The goal of the HOST-BR trial was to determine the optimal duration of dual antiplatelet therapy (DAPT) for patients who were stratified by high or low bleeding risk after receiving PCI with drug-eluting stent.
The routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions.
Ultimately the patient went to Cath and was found to have multi-vessel obstructive coronary disease with an acute LCX culprit vessel, which was stented. link] [link] Here’s a recent article from the JACC that not only summarizes previous WCT ECG research (eg, Brugada, Vereckei, etc), but presents a novel algorithm that may perform better.
7 The use of antiplatelet agents to prevent stent thrombosis, moderate- to high-dose statin therapy after acute coronary syndromes, or antihypertensive agents in asymptomatic patients may all be perceived by patients as not providing benefit because they may not feel the effects.8
She was taken to the cath lab, where she was found to have 100% in-stent restenosis of the proximal LAD. HYPERACUTE T-WAVES ARE EASILY RECOGNIZED BY THE QUEEN OF HEARTS HYPERACUTE T-WAVES DO NOT EVOLVE INTO ST ELEVATION -- THIS IS A MYTH Pendell and I are about to submit an article on ECG findings in total 100% LAD Occlusion (LAD OMI).
The goal of the ILUMIEN IV: OPTIMAL PCI trial was to evaluate optical coherence tomography (OCT)-guided revascularization compared with angiography-guided revascularization among patients undergoing percutaneous coronary intervention (PCI).
What is the evidence comparing dual antiplatelet therapy (DAPT) de-escalation to ticagrelor monotherapy versus continuing DAPT for 12 months after coronary drug-eluting stent implantation?
He then discusses paclitaxel-coated balloon catheters vs uncoated balloon angioplasty for treating coronary in-stent restenosis. Eagle looks at the difference between quantitative coronary angiography versus intervascular ultrasound to guide PCI.
The goal of the ECLIPSE trial was to evaluate orbital atherectomy prior to drug-eluting stent (DES) implantation compared with conventional percutaneous coronary intervention (PCI) without atherectomy among patients with calcified coronary lesions.
That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. Three interactive cases were treated with the drug-coated balloon and all patients were same-day discharged.
The following are key points to remember from an updated network meta-analysis on intravascular imaging-guided coronary drug-eluting stent (DES) implantation.
I would expect that a stent would be placed. The angiogram showed an open artery with 95% stenosis and thrombosis and it was stented. I would expect TIMI-3 flow (normal flow, no persistent ischemia) with a culprit in the RCA (or possibly Circumflex). They were interpreted as completely NORMAL!! Jesse McLaren et al.
Continuing aspirin monotherapy for patients with previous drug-eluting stents (DES) who are undergoing low-to-intermediate risk noncardiac surgery did not significantly reduce ischemic events compared with temporarily holding all antiplatelet therapy before the surgery, according to findings from the ASSURE DES trial presented at ESC Congress 2024 (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content